TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
May 25, 2023 01:20 JST
Source:
Northway Biotech
Northway Biotech Set to Launch Advanced Microbial and Mammalian GMP Facilities in Massachusetts
WALTHAM, MA, May 25, 2023 - (ACN Newswire) - Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape.
Northway Biotech Set to Launch Advanced Microbial and Mammalian GMP Facilities in Massachusetts
This recent growth is an extension of the successful launch of Northway Biotech's process and analytical development laboratories in Waltham (Greater Boston area) in 2020. The expanded facility now includes state-of-the-art cGMP suites, marking a significant milestone in the company's journey. The newly established cutting-edge biomanufacturing suites host a microbial fermentation train with up to 450 liters of volume capacity, and a mammalian production train with the ability to handle volumes of up to 2,000 liters. Northway Biotech has further established a specialized, fully automated fill and finish line to accommodate its clients' varied needs, supporting high-throughput filling into vials, syringes, and cartridges.
Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech, shared his insights regarding this accomplishment, stating, "The addition of GMP suites in our US site represents a transformative step for our organization, enabling us to provide comprehensive end-to-end solutions from our second site now. We are poised to transition current process development projects into the cGMP manufacturing phase in a timely manner, in line with our clients' committed schedules. Additionally, our longstanding US partners who have engaged with our Lithuanian site can now also take advantage of the geographical convenience of our modern facilities located in the Greater Boston Area. With our fully functional and technologically advanced manufacturing site at our disposal, Northway Biotech is perfectly positioned to take on manufacturing projects aimed at both clinical and commercial supply."
To commemorate this significant expansion and express gratitude to its valued partners and industry leaders, Northway Biotech will be hosting a grand opening event for its cGMP suites on June 8. This event promises to be an occasion of celebration and networking, providing an opportunity for attendees to witness firsthand the state-of-the-art facilities and engage in meaningful discussions within the biotech community.
About Northway Biotech -
https://www.northwaybiotech.com
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately-owned company founded in 2004 and located in Vilnius, Lithuania; London, United Kingdom; and Waltham, Massachusetts, United States.
For Further Information, Contact:
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
Source: Northway Biotech
Sectors: BioTech, Healthcare & Pharm
Copyright ©2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
July 15 2025 16:00 JST
Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards
May 05 2025 19:30 JST
Micreos Pharmaceuticals Partners With Biologics CDMO Northway Biotech for Its Engineered Endolysin Therapeutic Manufacturing Program
March 04 2025 20:00 JST
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
February 04 2025 18:00 JST
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology
August 01 2023 20:00 JST
tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
May 17 2023 06:00 JST
More Press release >>
Latest Press Release
JCB Celebrates 30 Years of Trust, Honoring 70 Years of Japan-Philippines Friendship
Jul 17, 2026 10:00 JST
TANAKA Commences Operation of "TANAKA H2 Nexus", One of Japan's Largest 500 kW Pure Hydrogen Fuel Cell Power Generation Facilities
Jul 16, 2026 22:00 JST
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Jul 16, 2026 00:18 JST
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Jul 15, 2026 23:51 JST
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 15, 2026 23:21 JST
NEC develops world's first proprietary-AI technology to rapidly generate highly detailed 3D models solely from general-purpose camera footage while automatically removing unnecessary subjects
Jul 15, 2026 22:53 JST
Hitachi Rail achieves EcoVadis platinum medal, ranking among the top 1% of companies worldwide for sustainability performance
Jul 15, 2026 22:35 JST
Anime Tokyo Station Reaches 300,000 Visitors!
Jul 15, 2026 11:00 JST
Fujitsu launches AI-driven modernization service to accelerate legacy system transformation
Jul 14, 2026 19:12 JST
Anime Tokyo Station: TV Anime "BLEACH: THE BLOOD WARFARE - The Calamity" Special Exhibition
Jul 14, 2026 11:00 JST
JCB Signs Memorandum of Understanding with Circle to Explore Collaboration Utilizing Stablecoins
Jul 14, 2026 10:00 JST
Mitsubishi Power Receives Contract to Supply Boilers for Fuel Conversion Work at Existing Thermal Power Plants in Saudi Arabia
Jul 14, 2026 00:58 JST
Fujitsu developed an AI Agent to collaborate with store managers for AEON Food Style's strategic store operations
Jul 14, 2026 00:38 JST
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 14, 2026 00:06 JST
Hitachi Digital Services announces partnership with ServiceNow to advance AI-powered solution for mission-critical infrastructure monitoring
Jul 13, 2026 23:35 JST
MHI Demonstrates Energy Efficiency Improvements through Cooling Optimization in Operational Data Center
Jul 13, 2026 23:00 JST
Mitsubishi Motors and Highlanders Sign MOU to Establish a New Industrial Foundation Where Humans and Robots Work Together
Jul 13, 2026 22:24 JST
Aflac Life Insurance Japan and The Cancer Institute Hospital of JFCR adopt Fujitsu's Medical Certificate Integration Service for online claim completion
Jul 13, 2026 21:56 JST
JCB, Resona and ODAWARA MOU to Advance Hands-Free UWB Payments for a Next-Generation Bus Experience
Jul 09, 2026 10:00 JST
MUFG Bank and JCB Sign MOU for Comprehensive Strategic Alliance in ASEAN
Jul 06, 2026 13:30 JST
More Latest Release >>